Impfungen/ vaccinations » Johnson & Johnson

Letzte Änderung: 26.01.2021 um 12:57 Uhr

Johnson & Johnson entwickeln einen Impfstoff, bei dem in einer Studie erforscht wird, ob evtl. nur eine Impfdosis erforderlich ist. Es ist ein Adenovirus- Vektorimpfstoff.

Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype vector encoding a full-length and stabilized SARS-CoV-2 spike protein.

Five serious adverse events in the phase 1-2a trial occurred:

one case of hypotension (unrelated to the vaccine because of a history of recurrent hypotension)

one case of bilateral nephrolithiasis (participant with a history of kidney stones/ not related)

one case of legionella pneumonia (not related)

one worsening of multiple sclerosis (which had remained undiagnosed for approximately 8 to 10 years on the basis of findings on magnetic resonance imaging (not related))

one case of fever that resulted in hospitalization because of suspicion of Covid-19

Weiterführende Links zum Artikel